SILICON VALLEY, CA — November 18, 2025 — Leads & Copy — ABVC BioPharma, Inc. (NASDAQ: ABVC) has received an additional $240,000 licensing payment from its partner OncoX BioPharma, Inc. under their existing licensing agreement. This brings the total licensing payments received from OncoX in 2025 to approximately $935,950, and the total since the collaboration began to approximately $1,135,950.
ABVC’s consolidated licensing revenue, which includes payments from all current licensing partners such as AiBtl BioPharma Inc. and ForSeeCon Eye Corporation, amounts to approximately $1,835,950 year-to-date in 2025 and approximately $2,531,950 since 2024.
The licensing agreement with OncoX covers four oncology product candidates licensed from ABVC and BioLite, Inc., targeting myelodysplastic syndrome (MDS), triple negative breast cancer (TNBC), pancreatic cancer, and non-small cell lung cancer (NSCLC).
OncoX recently completed two strategic acquisitions – an aesthetic medical group and a lycopene-based botanical oncology platform. The company internally assessed its combined business at an estimated value of $147 million, consisting of approximately $105 million for the licensed oncology assets, $18 million for aesthetic clinic assets, $14 million for the lycopene platform, and $10 million for AI and R&D-related value.
Dr. Uttam Patil, ABVC’s Chief Executive Officer, stated that the licensing and equity-based collaboration model helps build a stable revenue foundation while expanding access to innovative assets with long-term global potential. He believes this structure positions the Company to create sustained value for its shareholders over time.
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company currently has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has shown promising safety and efficacy in in-house trials and early-phase clinical studies. It has received four INDs (Investigational New Drug Applications) approved by the U.S. FDA.
In addition to its therapeutic pipeline, OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. The company has acquired the Lycogen® extraction platform to enter adjacent fields including preventative medicine, chronic disease care (such as benign prostatic hyperplasia, diabetic wound healing), aesthetic medicine, and animal health. These cross sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research.
OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA registered facility. The company seeks to expand its global footprint, with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets. OncoX is currently preparing for future clinical milestones and pursuing long-term international partnerships to bring its innovative therapies to patients worldwide.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Uttam Patil
Email: uttam@ambrivis.com
Source: ABVC BioPharma, Inc.
